Any trials or progress with imaging diagnostics, esp for post-diagnosis surveillance? (metastatic population often denied trial enrollment due to RECIST criteria). #lobular #BCSM

Probably getting way ahead of myself... but anyone exploring Immuno-Oncology approaches beyond checkpoint blockade? Any potential/attractive cell surface targets that could be exploited with CAR-T or CAR-NK approaches? #BCSM #lobular

Is it unrealistic to create an ILC tissue bank to accelerate discoveries? Can the tissue collected by the MBCproject be leveraged? I recall hearing that Genomic Health (OncotypeDX) has 30,000+ ILC tissue samples. Is that accessible / recyclable? #BCSM #lobular

Wonderful news about Steve Rosenberg, Jim Allison & Carl June for 2018 Albany Med Health System Prize in Medicine & Biomedical Research. Their development of immunotherapy to treat cancer is being recognized for "altering the course of medical research." Congratulations to 3 Great Scientists!

Visitor of the Week: Koen Schipper currentexchange.cshl.edu/blog/2018/8/vi… One of the scientists unraveling #Lobular BC. Thankful for Jos Jonkers Lab in the Netherlands. Still, the ILC research community is small and there’s plenty of room for more discoveries & researchers.

Today, hospital said it was reducing $108,000 out-of-pocket bill to $782?! Kaiser Health News' Chad Terhune NPR. Having a journalist's expose settle a bill is not triumph, it's a symptom of a very broken system, as in my book #AnAmericanSickness khn.org/news/a-jolt-to…

Tumor-suppressor genes are often inactivated through changes in mRNA processing that enable expression of truncated proteins. This mechanism of inactivation does not require DNA mutations in the affected genes. mskcc.org/blog/scientist…

Intra-lesion genetic heterogeneity in LCIS should be considered in studies aiming to develop biomarkers of progression from LCIS to invasive disease.

Wow! Didn’t realize Dr. Leisha Emens was at UPMC. As a thought leader in immunotherapy for breast cancer, this is a big win for Pitt and perhaps a potential windfall for the #Lobular community.

More pre-clinical evidence that suggests synergy between CDK4/6 inhibitors and Checkpoint Blockade to overcome resistance. Perhaps endocrine-sensitive tumors like #Lobular could benefit. Clinical trials needed.

Bringing together Clinical and Biomedical Scientists Cancer Center UMCU for the 1st European #ILC consortium meeting. Inspiring interactive sessions building towards an improved diagnosis and tailored treatment of #lobular #breastcancer! #ILBC #DerksenLab #UMCUtrecht

Adrian Lee I think it’s a good bet. There could be some kinks, but it is the most promising. Right now, the best guides to continue therapy are clinical: high grade, +nodes, HER2+, and lobular histology. It all of course has to be weighed in the context of comorbidities, toxicity, etc.

Impassion 130: PD-L1 expression on TILs best predictor of benefit from atezo (immune checkpoint inhibitor). Even expression at 1% level showed benefit. All metastatic TNBC should be tested for PD-L1 on TILs. #SABCS18 Atezo likely to be FDA approved in this setting in near future

#SABCS18 Desmedt on lobular cancer progression and endocrine resistance. Uses 73 matched primary and mets (great). Increased ESR1, IGF1R, HER2 mutations. Increased AKT1. Each of these has potential to alter therapy.

#SABCS18 genomic and immune characterization of lobular breast cancer presented by Dr. Desmedt underscores the fact that lobular breast cancer is different from ductal both clinically and in the mutations that occur. Need to think about optimal treatment strategies! #bcsm

Small historical studies reveal ~50% of Lobular breast cancers over-express ROR1 (not to be confused with ROS1). If validated, could Anti-ROR1 CAR-T immunotherapy be a future option for mILC? CAR T-Cell Therapy Shows Early Potential in TNBC shar.es/aaYRVD via @onclive

Susan Potter (breast cancer survivor) gave her body to science. Her cadaver became immortal. nationalgeographic.com/magazine/2019/… via National Geographic

Great news for the #Lobular breast cancer community. New Lobular Breast Cancer Registry Will Shed Light on Rare Disease consultqd.clevelandclinic.org/new-lobular-br… via Cleveland Clinic MD

#Lobular related abstracts at #AACR19 TMB, PD-L1 status & Checkpoint Inhibitors abstractsonline.com/pp8/?sf1004231… [18F]FDG PET/CT imaging abstractsonline.com/pp8/?sf1004231… NCI-MATCH EAY131 arm B: Phase II study of afatinib in patients with HER2 (ERBB2) activating mutations abstractsonline.com/pp8/?sf1004231…

Great news!